Pyxis Oncology, Inc. (PYXS)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | 2,820 | - | - | |
| Research and development | 17,133 | 17,044 | 17,741 | |
| General and administrative | 5,437 | 5,870 | 6,013 | |
| Total costs and operating expenses | 22,570 | 22,914 | 23,754 | |
| Loss from operations | -19,750 | -22,914 | -23,754 | |
| Sublease income | 684 | 515 | 705 | |
| Interest and investment income | 995 | 1,241 | 1,846 | |
| Total other income, net | 1,679 | 1,756 | 2,551 | |
| Loss before income taxes | -18,071 | - | - | |
| Income tax expense | 283 | - | - | |
| Net loss | -18,354 | -21,158 | -21,203 | |
| Net unrealized loss on marketable debt securities | -54 | -121 | 453 | |
| Other comprehensive loss | -54 | -121 | 453 | |
| Comprehensive loss | -18,408 | -21,279 | -20,750 | |
| Earnings per share, basic, total | -0.3 | -0.35 | -0.35 | |
| Earnings per share, diluted, total | -0.3 | -0.35 | -0.35 | |
| Weighted average number of shares outstanding, basic, total | 61,918,826 | 61,048,948 | 60,715,041 | |
| Weighted average number of shares outstanding, diluted, total | 61,918,826 | 61,048,948 | 60,715,041 | |